Guangdong Hybribio Biotech Co.,Ltd. (300639.SZ) announced that its wholly-owned subsidiary, Guangzhou Hybribio Pharmaceutical Technology Co., Ltd., has recently obtained the "Medical Device Registration Certificate (In Vitro Diagnostic Reagent)" issued by the National Medical Products Administration for its product, the "Norovirus Nucleic Acid Detection Kit (Fluorescent PCR Method)."

The acquisition of this product registration certificate enhances the company's product portfolio, meets diverse market demands, and further enriches its range of product offerings. This development supports the company's progress toward its overarching goal of becoming a leading enterprise in nucleic acid molecular diagnostics. It aligns with the company's strategic plan, "Nucleic Acid 99," and is expected to have a positive impact on its future business operations and growth.